Atossa Genetics Inc. (NASDAQ:ATOS) Sees Large Decline in Short Interest

Atossa Genetics Inc. (NASDAQ:ATOS) was the recipient of a significant decline in short interest in the month of February. As of February 13th, there was short interest totaling 408,724 shares, a decline of 91.3% from the January 29th total of 4,696,759 shares. Based on an average trading volume of 311,677 shares, the days-to-cover ratio is currently 1.3 days. Currently, 5.2% of the shares of the company are short sold. Currently, 5.2% of the shares of the company are short sold. Based on an average trading volume of 311,677 shares, the days-to-cover ratio is currently 1.3 days.

Atossa Genetics Stock Down 1.1%

NASDAQ ATOS traded down $0.05 during trading on Friday, hitting $4.42. 29,838 shares of the stock traded hands, compared to its average volume of 170,894. The company has a market capitalization of $38.08 million, a P/E ratio of -1.23 and a beta of 1.36. Atossa Genetics has a 12-month low of $3.76 and a 12-month high of $19.35. The firm has a 50-day simple moving average of $7.69 and a 200-day simple moving average of $10.89.

Institutional Trading of Atossa Genetics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd purchased a new position in Atossa Genetics in the 2nd quarter worth about $321,000. Graham Capital Management L.P. grew its position in shares of Atossa Genetics by 27.8% in the 4th quarter. Graham Capital Management L.P. now owns 211,369 shares of the company’s stock worth $125,000 after buying an additional 45,923 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of Atossa Genetics by 51.3% during the 4th quarter. Bank of America Corp DE now owns 111,475 shares of the company’s stock valued at $105,000 after purchasing an additional 37,809 shares during the last quarter. XTX Topco Ltd grew its stake in shares of Atossa Genetics by 581.2% during the fourth quarter. XTX Topco Ltd now owns 169,261 shares of the company’s stock worth $100,000 after acquiring an additional 144,412 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Atossa Genetics by 1,294.2% in the third quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after buying an additional 35,474 shares during the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Ascendiant Capital Markets boosted their price target on Atossa Genetics from $116.25 to $120.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $95.00.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.